Date of report 29 Jun 2023
Reported case interaction between
Cobicistat and CLOPIDOGREL
Cobicistat and CLOPIDOGREL
Drugs suspected to be involved in the DDI
Complete list of drugs taken by the patient
Clopidogrel 75 mg/24h acetylsalicylic acid 100mg/24h Atorvastatin 40 mg/24h
Clinical case description
59 year-old man with HIV diagnosed in 1985. Virologically suppressed since 2006. In June 2022 CD4 count 345/mm3 (17%) and HIV-1 RNA <50 copies/mL. Current ART with TAF/FTC/DRV/cobi since 2016 (previously TDF/FTC + DRV/rtv since 2008).
In August 2022 he was hospitalized because an acute myocardial infarction. After a primary angioplasty, the treatment prescribed was: clopidogrel (600 mg as loading dose and then 75 mg/24h, acetylsalicylic acid 100 mg/24h and atorvastatin 40 mg/24h)
Although no early thrombosis of a coronary stent or other complication was observed after 1 month of cobicistat and clopidogrel coadministration, probably the short period of coadministration, ART was switched to BIC/FTC/TAF to avoid such complications.
Clopidogrel is a prodrug and is converted to its active metabolite via CYPs 3A4, 2B6, 2C19 and 1A2. Coadministration of clopidogrel with potent CYPs 3A4 inhibitors such as cobicistat can decrease the concentration clopidogrel’s active metabolite and subsequently the desired effect of clopidogrel.
Clinical Outcome
Editorial Comment
Coadministration of clopidogrel and boosted regimens is contraindicated. Clopidogrel is a prodrug and is converted to its active metabolite via CYPs 3A4, 2B6, 2C19 and 1A2. Exposure of clopidogrel active metabolite was reduced by 96% in HIV-infected patients treated clopidogrel while on a ritonavir- or cobicistat- containing antiretroviral regimen compared to healthy volunteers receiving only clopidogrel. This may result in insufficient platelet inhibition in as much as in 44% of HIV-infected patients. If the booster cannot be avoided, consider safer alternatives such as prasugrel.
University of Liverpool Recommendation
These drugs should not be coadministered